Clinical Trial Update: PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of PHE885 CAR-T Therapy for adults with relapsed and refractory multiple myeloma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• PHE885 CAR-T Therapy

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED